Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-Versus-Host Disease with Prednisone and Everolimus (PredEver first): A Prospective Multicenter Phase IIa Study

Francis Ayuketang Ayuk, MD, Eva Maria Wagner, MD, Daniel Wolff, MD, Stephanie von Harsdorf, MD, Christian Koenecke, MD, Herbert G. Sayer, MD PhD, Nicolaus Kroeger, MD

Blood (2019) 134 (Supplement_1): 4523.

https://doi.org/10.1182/blood-2019-129801

Published: 2019

Journal Articles

Risk Factors Determining the Outcome of Critically Ill Allogeneic Hematopoietic Stem Cell Transplantation Patients: Time to Step Down?

Verena Wais, MD, Carmen Huwe, Armin Imhof, Hendrik Bracht, Thanh Mai Anne Nguyen, MD, Elisa Sala, MD, Hartmut Döhner, MD, Stephanie von Harsdorf, MD, Donald Bunjes, MD, Florian Kuchenbauer, MD PhD

Blood (2018) 132 (Supplement 1): 2135.

https://doi.org/10.1182/blood-2018-99-115280

Published: 2018

Journal Articles

Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: The Role of Calcineurin Inhibitors

Elisa Sala, MD, Stephanie von Harsdorf, MD, Verena Wais, MD, Thanh Mai Anne Nguyen, MD, Raphael Beck, MD, Hartmut Döhner, MD, Donald Bunjes, MD, Florian Kuchenbauer, MD PhD

Blood (2018) 132 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2018-99-114977

Published: 2018

Journal Articles

Reduced Intensity Conditioning with Fludarabine, BCNU and Melphalan (FBM) for Allogeneic Hematopoietic Cell Transplantation in Elderly AML Patients: Factors Predicting Outcome

Verena Wais, Stephan Bohl, Lukas Kündgen, Stephanie von Harsdorf, Katrina Scholl, Richard F. Schlenk, MD, Susanne Hofmann, C. Philipp Maier, Konstanze Döhner, MD, Maria-Veronica Teleanu, MD, Lars Bullinger, MD, Kathrin Drognitz, Jean-Charles Moulin, Martin Binnenhei, Martin Bentz, MD, Hartmut Döhner, MD, Donald Bunjes, MD, Mark Ringhoffer, MD, Florian Kuchenbauer, MD PhD

Blood (2015) 126 (23): 5523.

https://doi.org/10.1182/blood.V126.23.5523.5523

Published: 2015

Journal Articles

Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study

Wolfgang A. Bethge, Thoralf Lange, Christoph Meisner, Stephanie von Harsdorf, Martin Bornhaeuser, Birgit Federmann, Michael Stadler, Lutz Uharek, Matthias Stelljes, Stefan Knop, Gerald Wulf, Rudolf Trenschel, Vladan Vucinic, Helmut Dittmann, Christoph Faul, Wichard Vogel, Lothar Kanz, Donald Bunjes

Blood (2010) 116 (10): 1795–1802.

https://doi.org/10.1182/blood-2010-02-270538

Published: 2010

Journal Articles

Validation of the NIH Criteria of the Severity Grading of Chronic Gvhd – Results of a Prospective German Multicenter Validation Trial.

Daniel Wolff, Philipp Herzberg, Pia Heussner, Friederike Mumm, Inken Hilgendorf, MD, Stephanie von Harsdorf, MD, Philipp Hemmati, Armin Gerbitz, MD, Michael Schmitt, Ernst Holler, PhD, Hildegard Greinix

Blood (2009) 114 (22): 204.

https://doi.org/10.1182/blood.V114.22.204.204

Published: 2009

Journal Articles

Dose Escalated Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Aggressive Non-Hodgkin Lymphoma: An Interim Analysis of a Phase I/II Study

Wolfgang A Bethge, MD, Stephanie von Harsdorf, MD, Martin Bornhauser, MD, Dietrich Beelen, MD, Matthias Stelljes, MD, Rainer Schwerdtfeger, MD, Lutz Uharek, Birgit Federmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Helmut Dittmann, MD, Lothar Kanz, MD, Donald Bunjes, MD

Blood (2008) 112 (11): 2995.

https://doi.org/10.1182/blood.V112.11.2995.2995

Published: 2008

Journal Articles

Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Indolent Non-Hodgkin Lymphoma: Interim Analysis of a Phase II Study.

Wolfgang A Bethge, MD, Thoralf Lange, MD, Stephanie von Harsdorf, MD, Martin Bornhauser, MD, Birgit Federmann, MD, Michael Stadler, MD, Lutz Uharek, Stefan Knop, MD, Gerald Wulf, MD, Helmut Dittmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Donald Bunjes, MD

Blood (2008) 112 (11): 1959.

https://doi.org/10.1182/blood.V112.11.1959.1959

Published: 2008

Journal Articles

Severity of Chronic Gvhd and Personality Determines Quality of Life and the Activity Profile: Results of a Prospective German Multicenter Validation Trial

Daniel Wolff, MD, Philipp Herzberg, Pia Heussner, MD, Friederike Mumm, MD, Inken Hilgendorf, MD, Stephanie von Harsdorf, MD, Armin Gerbitz, MD, Hildegard T. Greinix, MD, Joachim Hahn, MD, Christian Junghanss, MD, Ernst Holler, PhD

Blood (2008) 112 (11): 742.

https://doi.org/10.1182/blood.V112.11.742.742

Published: 2008

Journal Articles

Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Non-Hodgkin Lymphoma: A Phase I/II Study.

Wolfgang A. Bethge, MD, Lange Thoralf, MD, Martin Bornhaeuser, MD, Michael Stadler, MD, Lutz Uharek, MD, Stefan Knop, MD, Stephanie von Harsdorf, MD, Vladan Vucinic, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Donald Bunjes, MD

Blood (2007) 110 (11): 3059.

https://doi.org/10.1182/blood.V110.11.3059.3059

Published: 2007

Journal Articles

Prospective Evaluation of the NIH Staging Criteria in Chronic GVHD and Correlation to Quality of Life - Results of a German Multicenter Validation Trial.

Daniel Wolff, MD, Philipp Y. Herzberg, Pia Heussner, MD, Friederike Mumm, MD, Stephanie von Harsdorf, MD, Katrin Rieger, MD, Hildegard Greinix, Joachim Hahn, MD, Ernst Holler, Mathias Freund

Blood (2007) 110 (11): 42.

https://doi.org/10.1182/blood.V110.11.42.42

Published: 2007

NARROW

Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-Versus-Host Disease with Prednisone and Everolimus (PredEver first): A Prospective Multicenter Phase IIa Study

Risk Factors Determining the Outcome of Critically Ill Allogeneic Hematopoietic Stem Cell Transplantation Patients: Time to Step Down?

Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: The Role of Calcineurin Inhibitors

Reduced Intensity Conditioning with Fludarabine, BCNU and Melphalan (FBM) for Allogeneic Hematopoietic Cell Transplantation in Elderly AML Patients: Factors Predicting Outcome

Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study

Validation of the NIH Criteria of the Severity Grading of Chronic Gvhd – Results of a Prospective German Multicenter Validation Trial.

Dose Escalated Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Aggressive Non-Hodgkin Lymphoma: An Interim Analysis of a Phase I/II Study

Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Indolent Non-Hodgkin Lymphoma: Interim Analysis of a Phase II Study.

Severity of Chronic Gvhd and Personality Determines Quality of Life and the Activity Profile: Results of a Prospective German Multicenter Validation Trial

Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Non-Hodgkin Lymphoma: A Phase I/II Study.

Prospective Evaluation of the NIH Staging Criteria in Chronic GVHD and Correlation to Quality of Life - Results of a German Multicenter Validation Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only